Olaratumab + Doxorubicin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Soft Tissue
Conditions
Sarcoma, Soft Tissue
Trial Timeline
Jan 22, 2015 → Nov 2, 2018
NCT ID
NCT02326025About Olaratumab + Doxorubicin
Olaratumab + Doxorubicin is a phase 1 stage product being developed by Eli Lilly for Sarcoma, Soft Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT02326025. Target conditions include Sarcoma, Soft Tissue.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02783599 | Phase 1 | Completed |
| NCT02377752 | Phase 1 | Completed |
| NCT02326025 | Phase 1 | Completed |
| NCT01185964 | Phase 1/2 | Completed |
Competing Products
20 competing products in Sarcoma, Soft Tissue